PMID- 38430027
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 70
IP  - 2
DP  - 2024 Feb 29
TI  - Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and 
      islet function of type 2 diabetes mellitus.
PG  - 156-160
LID - 10.14715/cmb/2024.70.2.22 [doi]
AB  - To investigate whether Liraglutide combined with Jinlida granules affects 
      glycolipid metabolism and islet function in the treatment of type 2 diabetes 
      mellitus (T2DM), a control group and an observation group were established with 
      90 T2DM patients. The control group was given Jinlida treatment and the 
      observation group was given liraglutide combined treatment for 12 weeks. The 
      clinical efficacy, glycolipid metabolism, bone metabolism, islet function, and 
      endothelial function. The curative effect of the observation group was better 
      than that of the control group. After treatment, FBG, 2hPG, HbAlc, TC, TG, and 
      LDL-C in the observation group were lower and HDL-C was higher than those in the 
      control group (P < 0.05). After treatment, the observation group showed higher 
      bone mineral density, osteocalcin, FINS, and HOMA-beta and lower HOMA-IR than the 
      control group (P < 0.05). After treatment, endothelin-1 level in the observation 
      group was lower than that in the control group, and the NO level was higher (P < 
      0.05). No significant difference was found in the incidence of adverse reactions 
      between the two groups (P > 0.05). Liraglutide combined with Jinlida in T2DM can 
      improve glucose, lipid, and bone metabolism, promote the recovery of islet 
      function, and enhance vascular endothelial function.
FAU - Wang, Xianjuan
AU  - Wang X
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. lpbbobo@163.com.
FAU - He, Kun
AU  - He K
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. hekun1616@126.com.
FAU - Li, Jing
AU  - Li J
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. 17603197268@163.com.
FAU - Liu, Ying
AU  - Liu Y
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. 15630900227@163.com.
FAU - Peng, Zhaokang
AU  - Peng Z
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. 19131917931@163.com.
FAU - Zhao, Lijuan
AU  - Zhao L
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. ZljLcyyk@163.com.
FAU - Ji, Shumin
AU  - Ji S
AD  - Department of Endocrinology, Xingtai Third Hospital, Xingtai City, Hebei 
      Province, 054000, China. jishumin123456@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20240229
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 839I73S42A (Liraglutide)
RN  - 0 (jinlida)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycolipids)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - Liraglutide/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Glycolipids/therapeutic use
MH  - *Drugs, Chinese Herbal
EDAT- 2024/03/02 12:44
MHDA- 2024/03/04 06:49
CRDT- 2024/03/02 04:32
PHST- 2023/12/05 00:00 [received]
PHST- 2024/03/04 06:49 [medline]
PHST- 2024/03/02 12:44 [pubmed]
PHST- 2024/03/02 04:32 [entrez]
AID - 10.14715/cmb/2024.70.2.22 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2024 Feb 29;70(2):156-160. doi: 
      10.14715/cmb/2024.70.2.22.